STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] Guardant Health, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Guardant Health (GH) Form 4: Director Steve E. Krognes reported the automatic conversion of 154 restricted stock units (RSUs) into an equal number of common shares on 07/31/2025 (transaction code “M”). No shares were sold. The RSUs stem from an August 9 2022 grant that vested 25 % on 06/30/2023; the remaining 75 % continue to vest in equal monthly installments through mid-2026.

Following the conversion, Krognes now holds 17,973 shares directly and retains 1,698 un-settled RSUs. The transaction was priced at $0, indicating a standard equity award settlement rather than an open-market purchase. Ownership structure remains direct, and no 10b5-1 plan was indicated.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Small RSU vesting; negligible market impact.

The filing shows routine settlement of 154 RSUs from a 2022 grant. No cash purchase, no sales, and ownership rises marginally to 17,973 shares plus 1,698 RSUs. Because the quantity is immaterial relative to GH’s 106 M share float, signal value for investors is minimal. It does, however, reaffirm ongoing equity-based compensation alignment for an outside director, which is standard governance practice rather than a directional bet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Krognes Steve E.

(Last) (First) (Middle)
3100 HANOVER STREET

(Street)
PALO ALTO CA 94304

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/31/2025 M 154 A $0 17,973 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0 07/31/2025 M 154 (1) (2) Common Stock 154 $0 1,698 D
Explanation of Responses:
1. This represents a restricted stock unit award granted on August 9, 2022 that vested 25% of the shares subject to such award `on June 30, 2023. The remaining 75% of the shares subject to such award vest in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter.
2. Not applicable for Restricted Stock Units.
Remarks:
/s/ John Saia, as attorney-in-fact for Steve Krognes 08/04/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Guardant Health (GH) shares did Steve Krognes acquire?

He acquired 154 common shares through the vesting of restricted stock units.

What is Steve Krognes’ total direct share ownership after the transaction?

Direct ownership increased to 17,973 GH shares.

Were any shares sold in this Form 4 filing?

No. The filing reports only the acquisition of shares via RSU conversion; no sales occurred.

What is the origin of the RSUs that vested on 07/31/2025?

They are part of an August 9 2022 grant that vests 25 % on 06/30/2023 and monthly thereafter over three years.

Does the filing reference a Rule 10b5-1 trading plan?

No, the indicated 10b5-1 checkbox was not marked.
Guardant Health

NASDAQ:GH

GH Rankings

GH Latest News

GH Latest SEC Filings

GH Stock Data

14.45B
123.40M
4.5%
99.11%
6.43%
Diagnostics & Research
Services-medical Laboratories
Link
United States
PALO ALTO